Coronavirus Vaccine Candidate From Pfizer and BioNTech Leaps Over Efficacy Hurdle
Buck up campers, it might all be over soon. On Monday morning, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced success with their coronavirus vaccine candidate, BNT162b2, following the first interim analysis of a gigantic phase 3 trial.
Image source: Getty Images
The independent data monitors tasked with watching the phase 3 trial had been expected to conduct the first interim analysis once 32 trial participants had tested positive for COVID-19. Once the FDA, Pfizer, and BioNTech had finished discussing the merits of waiting for a minimum of 62 cases to conduct the first interim analysis, the number of volunteers that tested positive for COVID-19 had already reached 94.
Source Fool.com
